Alimera Sciences, Inc. (ALIM) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
6310 TOWN SQUARE ALPHARETTA, GA 30005 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,274 | 16,510 | 11,208 | 9,426 | 13,043 | 24,067 | |||
| Cash and cash equivalents | 5,274 | 16,510 | 11,208 | 9,426 | 13,043 | 24,067 | |||
| Restricted cash and investments | 30 | 34 | 34 | 33 | 32 | 34 | |||
| Receivables | 19,612 | 19,128 | 17,200 | 19,331 | 17,259 | 11,435 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,605 | 2,679 | 2,746 | 1,390 | 2,405 | 1,508 | |||
| Inventory | 1,605 | 2,679 | 2,746 | 1,390 | 2,405 | 1,508 | |||
| Other undisclosed current assets | 2,892 | 3,809 | 3,718 | 2,565 | 2,109 | 2,278 | |||
| Total current assets: | 29,413 | 42,160 | 34,906 | 32,745 | 34,848 | 39,322 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 392 | 414 | ✕ | ✕ | |||||
| Operating lease, right-of-use asset | 1,395 | 1,710 | 720 | 1,107 | ✕ | ✕ | |||
| Property, plant and equipment | 2,525 | 2,783 | 1,638 | 1,355 | 1,410 | ||||
| Intangible assets, net (including goodwill) | 8,957 | 10,897 | 12,838 | 14,783 | 16,723 | 18,664 | |||
| Intangible assets, net (excluding goodwill) | 8,957 | 10,897 | 12,838 | 14,783 | 16,723 | 18,664 | |||
| Deferred income tax assets | 129 | 137 | 753 | 734 | ✕ | ✕ | |||
| Other undisclosed noncurrent assets | 183 | 441 | 526 | 1,182 | 528 | ||||
| Total noncurrent assets: | 13,189 | 16,360 | 15,949 | 17,564 | 19,260 | 20,602 | |||
| TOTAL ASSETS: | 42,602 | 58,520 | 50,855 | 50,309 | 54,108 | 59,924 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 14,086 | 12,323 | 10,658 | 11,793 | 9,998 | 9,487 | |||
| Accounts payable | 10,088 | 8,706 | 7,461 | 7,077 | 6,355 | 5,905 | |||
| Accrued liabilities | 3,998 | 3,617 | 3,197 | 4,716 | 3,643 | 3,582 | |||
| Debt | 25,646 | 269 | 1,690 | 255 | 236 | 184 | |||
| Other undisclosed current liabilities | |||||||||
| Total current liabilities: | 39,732 | 12,592 | 12,348 | 12,048 | 10,234 | 9,671 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 18,683 | 43,080 | 42,922 | 94 | 305 | 34,568 | |||
| Long-term debt, excluding current maturities | 18,683 | 43,080 | 42,408 | 34,365 | |||||
| Capital lease obligations | ✕ | ✕ | ✕ | ✕ | ✕ | 305 | 203 | ||
| Finance lease, liability | 514 | 94 | ✕ | ✕ | |||||
| Liabilities, other than long-term debt | 4,995 | 5,453 | 3,563 | 3,954 | 2,974 | 766 | |||
| Other liabilities | 4,995 | 5,453 | 3,563 | 3,954 | 2,974 | 766 | |||
| Operating lease, liability | ✕ | ✕ | |||||||
| Other undisclosed noncurrent liabilities | |||||||||
| Total noncurrent liabilities: | 23,678 | 48,533 | 46,485 | 4,048 | 3,279 | 35,334 | |||
| Total liabilities: | 63,410 | 61,125 | 58,833 | 16,096 | 13,513 | 45,005 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (20,808) | (2,605) | (7,978) | (4,445) | 2,722 | 14,919 | |||
| Common stock | 70 | 69 | 57 | 50 | 701 | ||||
| Additional paid in capital | 378,238 | 377,229 | 365,830 | 350,117 | 346,108 | 341,622 | |||
| Accumulated other comprehensive loss | (2,955) | (1,849) | (553) | (1,093) | (1,011) | (821) | |||
| Accumulated deficit | (415,388) | (397,281) | (392,909) | (387,570) | (377,127) | (399,075) | |||
| Warrants and rights outstanding | 370 | 3,707 | 3,707 | ||||||
| Other undisclosed equity, attributable to parent | 19,227 | 19,227 | 19,227 | 30,344 | 30,344 | 73,193 | |||
| Total equity: | (20,808) | (2,605) | (7,978) | (4,445) | 2,722 | 14,919 | |||
| Other undisclosed liabilities and equity | 38,658 | 37,873 | |||||||
| TOTAL LIABILITIES AND EQUITY: | 42,602 | 58,520 | 50,855 | 50,309 | 54,108 | 59,924 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 54,129 | 59,029 | 50,820 | 53,943 | 46,970 | 35,912 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (7,977) | (7,030) | (6,941) | (6,626) | (3,438) | |||
| Other undisclosed gross profit | (4,679) | |||||||
| Gross profit: | 46,152 | 51,999 | 43,879 | 47,317 | 42,291 | 32,474 | ||
| Operating expenses | (57,792) | (52,200) | (44,380) | (52,591) | (51,961) | (48,926) | ||
| Operating loss: | (11,640) | (201) | (501) | (5,274) | (9,670) | (16,452) | ||
| Nonoperating income (expense) (Gain (Loss), Foreign Currency Transaction, before Tax) | 92 | 416 | 474 | (84) | (65) | 5 | ||
| Interest and debt expense | (5,881) | (3,621) | (5,380) | (4,869) | (6,541) | (5,579) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 188 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (17,429) | (3,406) | (5,407) | (10,227) | (16,276) | (21,838) | ||
| Other undisclosed loss from continuing operations before income taxes | (650) | (528) | ||||||
| Loss from continuing operations before income taxes: | (18,079) | (3,934) | (5,407) | (10,227) | (16,276) | (21,838) | ||
| Income tax expense (benefit) | (28) | (438) | 68 | (216) | (106) | (163) | ||
| Loss from continuing operations: | (18,107) | (4,372) | (5,339) | (10,443) | (16,382) | (22,001) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (4,372) | (5,339) | (10,443) | (16,382) | (22,001) | |
| Net loss attributable to parent: | (18,107) | (4,372) | (5,339) | (10,443) | (16,382) | (22,001) | ||
| Preferred stock dividends and other adjustments | 38,330 | |||||||
| Undistributed earnings (loss) allocated to participating securities, basic | 4,489 | |||||||
| Other undisclosed net loss available to common stockholders, basic | (4,489) | |||||||
| Net income (loss) available to common stockholders, diluted: | (18,107) | (4,372) | (5,339) | (10,443) | 21,948 | (22,001) | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (18,107) | (4,372) | (5,339) | (10,443) | (16,382) | (22,001) | ||
| Other comprehensive income (loss) | (82) | (190) | 451 | |||||
| Comprehensive loss: | (18,107) | (4,372) | (5,339) | (10,525) | (16,572) | (21,550) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (1,106) | (1,296) | 540 | |||||
| Comprehensive loss, net of tax, attributable to parent: | (19,213) | (5,668) | (4,799) | (10,525) | (16,572) | (21,550) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.